Each tablet contains 54 mg or 160 mg of fenofibrate
statin, fenofibrate, or other LDL-C lowering therapy are contraindicated
17 PATIENT COUNSELING INFORMATION * FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1
45 mg choline fenofibrate delayed release capsules with a reddish-brown cap imprinted in When used in combination with a n, fenofibrate, or other LDLstati C lowering therapy, - ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDLC lowering therapy - are contraindicated
g
Warnings and Precautions, Hepatotoxicity 03/2021
RECENT MAJOR CHANGES
See full prescribing information for 7
5
3)
In this review, we compare the key, clinically relevant characteristics of the fenofibrate formulations that are currently available, specifically focusing on comparative studies examining the bioavailability, food effects, and absorption of these fenofibrate formulations
Patients should also be advised to inform their physicians prescribing a new medication that they are taking fenofibrate tablets
Description for Fenofibrate 40 mg/ 120 mg
These highlights do not include all the information needed to use ROSUVASTATIN CALCIUM TABLETS increase with use of 40 mg dose, advanced age (greater than or equal to safely and effectively
8 USE IN SPECIFIC POPULATIONS
Fenofibrate, or Other LDL-C Lowering Therapies: Refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions
g
Trilipix is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as adjunctive therapy to diet to: Reduce TG in patients with severe hypertriglyceridemia ()
83; fenofibrate is insoluble in water
Elevations in serum creatinine have been reported in patients on fenofibrate
5 Fenoglide: Initial dose: 40 to 120 mg orally once a day; maximum dose: 120 mg/day
Therapeutic uses, prescribing information and product availability may vary between countries